| Literature DB >> 17998932 |
M Reinbold1, J-L Luo, T Nedelko, B Jerchow, M E Murphy, C Whibley, Q Wei, M Hollstein.
Abstract
Codon 72 of human p53 gene is polymorphic, encoding arginine or proline. Here we report construction of a human p53 knock-in (Hupki) mouse encoding the codon 72(pro) variant. The new strain was crossed with the original Hupki mice (codon 72(arg/arg)) to obtain primary embryonic fibroblasts polymorphic at codon 72 or homozygous for codon 72(pro). The fibroblasts, cultured under standard conditions, immortalized within 12 weeks and acquired p53 mutations similarly to Hupki codon 72(arg/arg) cells investigated previously. Sequencing of human p53 exons 4-9 in immortalized cultures revealed missense mutations found repeatedly in human tumours. In cell lines ensuing from benzo(a)pyrene-treated cultures the combined p53 mutation pattern from experiments with the 3 codon 72 genotypes showed a predominance of strand-biased G to T transversions (18 of 36 mutations), and mutations recurring at smokers' lung tumour hotspot codons 157 and 273, supporting involvement of tobacco carcinogens in shaping the mutation signature in lung cancers of smokers. Mutations in cell lines from unexposed cultures did not cluster at these codons and G to T transversions were uncommon (2 of 52 mutations) (Fisher's exact test P<0.0001). Most mutations (13/16) in cell lines derived from cells polymorphic at codon 72 were found on the proline allele, with loss of the arginine allele.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17998932 PMCID: PMC6813802 DOI: 10.1038/sj.onc.1210932
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867
Figure 1.Generation of new Hupki strain encoding proline at codon 72.
A. Targeting strategy. The CGC to CCC base substitution at codon 72 of the human p53 genomic DNA fragment (exons 4–9) of the Hupki targeting construct [Luo et al., 2001] was introduced by site-directed mutagenesis. Homologous recombinants from electroporated ES 14.1 cells were injected into C57Bl/6 blastocysts, producing chimeric offspring that were bred to generate progeny transmitting the Hupki codon72pro variant in Exon 4 (asterisk) through the germline. Mice from these colonies were bred with the Hupki codon72arg/arg strain to generate Hupki codon72arg/pro heterozygote mice. B. Southern blot analysis of genomic DNA from tails of Hupki codon72pro/pro and Hupki codon72arg/pro mice and sequencing of exon 4 confirmed the genotypes. Lane a: WT strain 129, with endogenous murine p53 (mp53WT). Lane b, Hupki codon72arg/arg (prototype strain; Luo et al., 2001). Lane c, Hupki codon72arg/pro heterozygote, Lane d, Hupki codon72pro/mp53WT heterozygote. Lane e, Hupki codon72pro/pro. Fragment I: Hupki allele; Fragment II: mp53WT allele; [Fragment III: mouse pseudogene]. DNA was digested with Bgl II and BamHI, and probed with sequences corresponding to murine p53 exon 11. Electropherograms showing the p53 codon72 site in genomic DNA from Hupkiarg/arg, pro/pro, and arg/pro mouse tails are shown on the right, panels 1–3. C. Phase contrast photomicrographs of primary (p.1), senescent (p.7) and immortalized (p.17) HUF codon72pro/pro cultures, (40x) (Panels 1–3).
P53 mutations in cell lines from codon72arg/pro and codon72pro/pro HUFs.
| Location of mutation | No. of mutations | No. of missense mutations1 | No. of missense mutations found in ≥ 5 human tumours | Frequently mutated codons |
|---|---|---|---|---|
| Exon 4 | 1 | 1 | 1 | |
| Exon 5 | 10 | 10 | 9 | 176 (3x) |
| Exon 6 | 2 | 2 | 2 | |
| Exon 7 | 10 | 9 | 9 | 245 (6x) |
| Exon 8–9 | 6 | 6 | 6 | 281 (4x) |
| Splice (intron) | 2 | - | - | |
| TOTAL | 31 | 28 | 27 | |
Figure 2.P53 Mutation patterns in immortalized cell lines from untreated and from benzo(a)pyrene-treated HUF cultures (all codon72 genotypes combined).
A. Type of base substitutions in human p53 coding sequences in immortalized cell lines from untreated HUF cultures (clear bars) and B(a)P treated (filled bars) cultures, all codon72 genotypes [Data are combined from this report (HUFarg/pro and HUFpro/pro Table 1), and from published data on HUFarg/arg cells [Liu et al., 2004, 2005 and Feldmeyer et al, 2006]. G to T mutations (*) are far more prevalent in p53 mutant cell lines from B(a)P treated cultures than in cell lines from untreated cultures, (2/52 vs. 18/36; Fisher’s exact test, p<0.0001) and reveal a strong strand bias: 17/18 G to T mutations occurred at sites where the pre-mutated guanine was positioned on the non-transcribed strand. B. Distribution of the 29 base substitutions along the p53 coding sequence in cell lines derived from B(a)P-treated HUF cultures (all HUF genotypes combined). (Note: Of 36 p53 sequence changes in cell lines from B(a)P treated cultures, 29 were single base substitutions in codons shown here. Additional single base substitutions were at splice sites (not depicted).
Prevalence of G to T mutations at selected codons of p53 in human lung, brain and colon tumours[1]
| Cancer type | No. of mutations in IARC Database | G to T mutations at codon 157 | G to T mutations at codon 273 |
|---|---|---|---|
| lung | 2544 | 53 (2.08%) | 52 (2.04 %) |
| brain | 1522 | 7 (0.46%)* | 4 (0.26 %)* |
| colon | 974 | 5 (0.51%)** | 3 (0.31 %)* |
| Cancer type | No. of mutations in IARC Database | G to T mutations at codon 176 | G to T mutations at codon 275 |
| lung | 2544 | 12 (0.47 %) | 6 (0.23 %) |
| brain | 1522 | 6 (0.39 %) ns | 8 (0.52 %) ns |
| colon | 974 | 4 (0.41 %) ns | 1 (0.10 %) ns |
The prevalence of G to T transversions at the hotspot codons 157 and 273 in human lung tumours harbouring a p53 mutation is significantly higher than the prevalence of these mutations in brain or colon tumours (A). For comparison, note that at codons 176 and 275, which are not lung tumour hotspots, the G to T prevalence is not exceptional in lung tumours (B).